טוען...
Use of Bone Morphogenetic Protein Among Patients Undergoing Fusion for Degenerative Diagnoses in the United States, 2002–2012
BACKGROUND CONTEXT: Use of Bone Morphogenetic Protein (BMP) as an adjunct to spinal fusion surgery proliferated following Food and Drug Administration (FDA) approval in 2002. Major safety concerns emerged in 2008. PURPOSE: To examine whether published concerns about the safety of BMP altered clinica...
שמור ב:
| הוצא לאור ב: | Spine J |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2014
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4375057/ https://ncbi.nlm.nih.gov/pubmed/25523380 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.spinee.2014.12.010 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|